Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Cash from Financing Activities: 2021-2022

Historic Cash from Financing Activities for Cardiol Therapeutics (CRDL) over the last 2 years, with Sep 2022 value amounting to -$10,615.

  • Cardiol Therapeutics' Cash from Financing Activities fell 100.57% to -$10,615 in Q3 2022 from the same period last year, while for Sep 2022 it was $47.0 million, marking a year-over-year change of. This contributed to the annual value of $13.8 million for FY2024, which is 33628.33% up from last year.
  • Latest data reveals that Cardiol Therapeutics reported Cash from Financing Activities of -$10,615 as of Q3 2022, which was down 2.01% from -$10,406 recorded in Q2 2022.
  • Cardiol Therapeutics' 5-year Cash from Financing Activities high stood at $47.0 million for Q4 2021, and its period low was -$10,615 during Q3 2022.
  • Its 2-year average for Cash from Financing Activities is $10.6 million, with a median of $1.9 million in 2021.
  • Data for Cardiol Therapeutics' Cash from Financing Activities shows a maximum YoY slumped of 100.57% (in 2022) over the last 5 years.
  • Quarterly analysis of 2 years shows Cardiol Therapeutics' Cash from Financing Activities stood at $47.0 million in 2021, then tumbled by 100.57% to -$10,615 in 2022.
  • Its last three reported values are -$10,615 in Q3 2022, -$10,406 for Q2 2022, and -$10,247 during Q1 2022.